CIPLAR LA 40MG TABLET

Ciplar-LA 40mg Tablet by Cipla is a long-acting, prescription-grade oral beta-blocker formulated to address a spectrum of cardiovascular and neurological conditions in animals, including hypertension, cardiac arrhythmias, stable angina, obstructive hypertrophic cardiomyopathy, and the prophylactic management of migraine-equivalent episodes. It is also indicated as adjunctive therapy in pheochromocytoma and thyrotoxicosis, and targets the management of essential tremor in veterinary patients where such presentations are clinically relevant. By delivering sustained-release propranolol over an extended dosing window, Ciplar-LA reduces dosing burden while maintaining consistent plasma-level control, making it the preferred choice of veterinary cardiologists managing chronic cardiovascular disease. Animeal is proud to offer Ciplar-LA 40mg Tablet as part of its curated range of prescription veterinary pharmaceuticals, supporting comprehensive cardiac care for your companion animal.

Ingredients:

Propranolol Hydrochloride (Propranolol HCl), 40mg per tablet, long-acting formulation:Propranolol Hydrochloride is a non-selective beta-adrenergic receptor antagonist that competitively blocks both beta-1 (cardiac) and beta-2 (vascular and bronchial) adrenoceptors. At the myocardial level, beta-1 blockade reduces the rate of spontaneous depolarisation of the sinoatrial node, thereby lowering resting heart rate and diminishing the force of ventricular contraction. This negative chronotropic and inotropic action decreases myocardial oxygen demand, which is the central mechanism through which propranolol alleviates angina pectoris. Through beta-2 blockade in peripheral vasculature, the drug attenuates renin release from juxtaglomerular cells in the kidney, suppressing the renin-angiotensin-aldosterone axis and producing a sustained reduction in systemic blood pressure. In the central nervous system, propranolol's lipophilic nature enables it to cross the blood-brain barrier, where it modulates adrenergic signalling implicated in migraine pathogenesis and essential tremor. The extended-release matrix of Ciplar-LA ensures a gradual, controlled absorption profile, maintaining therapeutic plasma concentrations over an extended period and minimising peak-trough fluctuations compared to immediate-release formulations.